PFO
MRK icon

Pathstone Family Office’s Merck MRK Stock Holding History

Pathstone Family Office’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-105
Closed -$1K – 1083
2020
Q4 		$1K Buy
+105
New +$8.03K ﹤0.01% 1103

Other funds holding MRK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Pathstone Family Office's MRK Position: Q3 2023 in Review

Pathstone Family Office increased its Merck (MRK) stake by 66% in Q3 2023, buying an estimated $16.1M and bringing the position to 374,273 shares worth $38.7M. The position accounts for 0.29% of the portfolio, ranked #55.

Pathstone Family Office first reported a position in MRK in Q2 2013 and has held it in 38 quarters since. The position peaked at $62.4M in Q4 2022. 3,213 funds tracked by Wall St. Rank hold MRK as of Q3 2023.

  • Pathstone Family Office held 374,273 shares of Merck worth $38.7M as of Q3 2023.
  • Pathstone Family Office bought 149,093 Merck shares in Q3 2023, an estimated $16.1M.
  • Merck made up 0.29% of Pathstone Family Office's portfolio in Q3 2023, its #55 holding.
  • Pathstone Family Office first reported a position in Merck in Q2 2013 and has held it in 38 quarters since.
  • Pathstone Family Office's Merck position peaked at $62.4M in Q4 2022.
  • 3,213 funds tracked by Wall St. Rank held Merck as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.